Mortality and complications in Omani patients with beta-thalassemia major: a long-term follow-up study

Mortality and complications in Omani patients with beta-thalassemia major: a long-term follow-up study

Authors

  • Shahina Daar
  • Khalid Al-Naamani
  • Vincenzo de Sanctis
  • Sarah Al Rahbi
  • Shoaib Al Zadjali
  • Hammad Khan
  • Vinodh Panjwani
  • Murtadha Al-Khabori a:1:{s:5:"en_US";s:24:"Sultan Qaboos University";} https://orcid.org/0000-0002-2937-8838

Keywords:

β -thalassemia major, Oman, Mortality, Morbidity, Long-term follow-up

Abstract

Background and aim:Beta thalassemia major (β-TM) is a genetic blood disorder requiring lifelong blood transfusions.  The resulting iron overload damages multiple organs, particularly the heart and endocrine organs. This study aimed to describe and assess the predictors of survival and complications in Omani patients with β-TM.

 

Methods: All β-TM patients registered in the day care of Sultan Qaboos University Hospital were included in this retrospective study.

 

Results: There were 187 patients with β-TM with a median follow-up of 24.9 years.  The median ages at diagnosis and the start of chelation were 0.7 and 4.8 years, respectively. The following complications developed at different time points [Median (age in years), Complication Free Probability at 20 years]: Death (20.0 years;85%), hypogonadism (15.9 years;50%), insulin-dependent or non-insulin dependent diabetes (20.0 years;88%), cardiac complications (20.3 years;91%), osteoporosis (20.7 years;96%), hypothyroidism (25.7 years;97%), liver complications (7.3 years;54%). The number of complications predicted death (P = 0.0038). Those born after 1980 had a lower risk of death (P = 0.005), hypogonadism (P = < 0.0001), and cardiac complications (P = 0.004). Higher serum ferritin at the start of chelation was associated with the development of diabetes (P = < 0. 001).

 

Conclusions: This long-term study shows complications development at different ages, and the number of complications is associated with survival. Later birth cohorts had a lower risk of death, hypogonadism, and cardiac complications. There was a persistent negative impact of delay in the start of iron chelation that is present even after a long follow-up. (www.actabiomedica.it).

References

Modell B, Khan M, Darlison M, et al. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008; 10(1):42. doi: 10.1186/1532-429X-10-42.

Borgna-Pignatti C, Rugolotto S, Stefano PD, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89(10):1187-93 PMID: 15477202.

Ladis V, Chouliaras G, Berdoukas V, et al. Survival in a large cohort of Greek patients with transfusion-dependent beta thalassaemia and mortality ratios compared to the general population. Eur J Haematol. 2011; 86(4):332–8. doi: 10.1111/j.1600-0609.2011.01582.x.

Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 2006; 91: 1187-92. PMID: 16956817.

Anderson L. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. European Heart Journal. 2001; 22(23):2171–9. doi: 10.1053/ euhj.2001.2822.

Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR, the Thalassemia Clinical Research Network Complications of β-thalassemia major in North America. Blood. 2004; 104(1):34–9. doi: 10.1182/blood-2003-09-3167.

Charafeddine K, Isma’eel H, Charafeddine M, et al. Survival and Complications of Beta-Thalassemia in Lebanon. Acta Haematol. 2008;120(2):112–6. doi: 10.1159/000171088.

Li CK, Luk CW, Ling SC, et al. Morbidity and mortality patterns of thalassaemia major patients in Hong Kong: retrospective study. Hong Kong Med J. 2002; 8(4):255-60. PMID: 12167729.

Kosaryan M, Vahidshahi K, Karami H, Forootan MA, Ahangari M. Survival of Thalassemic Patients Referred to the Boo Ali Sina Teaching Hospital, Sari, Iran. Hemoglobin. 2007; 31(4):453–62. doi: 10.1080/03630260701641294.

Rajaeefard A, Hajipour M, Tabatabaee HR, et al. Analysis of survival data in thalassemia patients in Shiraz, Iran. Epidemiol Health. 2015; 37:e2015031 doi: 10.4178/epih/ e2015031.

Sporea I, Bota S, Gradinaru-Taşcău O, Sirli R, Popescu A, Jurchiş A. Which are the cut-off values of 2D-Shear Wave Elastography (2D-SWE) liver stiffness measurements predicting different stages of liver fibrosis, considering Transient Elastography (TE) as the reference method? Eur J Radiol. 2014; 83(3):e118-22. doi: 10.1016/j.ejrad. 2013.12.011.

Kirk P, Roughton M, Porter JB, et al. Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major. Circulation. 2009; 120(20): 1961–8. doi: 10.1161/CIRCULATIONAHA.109.874487.

Carpenter J-P, Roughton M, Pennell DJ, Myocardial Iron in Thalassemia (MINT) Investigators. International survey of T2* cardiovascular magnetic resonance in beta-thalassemia major. Haematologica. 2013; 98(9):1368–74. doi: 10.3324/haematol. 2013. 083634.

Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127(3):348–55. doi: 10. 1111/j.1365-2141.2004.05202.x.

Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355(9220): 2051-2. doi: 10.1016/S0140-6736(00)02357-6.

Marsella M, Borgna-Pignatti C, Meloni A, et al. Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging study. Haematologica. 2011; 96(4):515–20. doi: 10.3324/haematol.2010.025510.

Pepe A, Gamberini MR, Missere M, et al. Gender differences in the development of cardiac complications: a multicentre study in a large cohort of thalassaemia major patients to optimize the timing of cardiac follow-up. Br J Haematol. 2018; 180(6):879–88. doi: 10.1111/bjh.15125.

Chouliaras G, Yiannoutsos CT, Berdoukas V, Ladis V. Cardiac related death in thalassaemia major: time trend and risk factors in a large Greek Unit. Eur J Haematol. 2009; 82(5):381–7. doi: 10.1111/j.1600-0609.2009.01218.x.

Al-Hafidh NM, Younis MS, Al Taee KF. Survival rate and mortality causes in patients with β-thalassemia major in Nineveh Governorate, Iraq. PJMHS 2020; 14(3):1274-77.

Pistoia L, Meloni A, Salvadori S, et al. Cardiac involvement by CMR in different genotypic groups of thalassemia major patients Blood Cells Mol. Dis. 2019; 77:1-7. doi: 10.1016/j.bcmd.2019.01.008.

Hassan TH, Abdel Salam MM, Zakaria M, et al. Impact of Genotype of Beta Globin Gene on Hepatic and Myocardial Iron Content in Egyptian Patients with Beta Thalassemia. Indian J Hematol Blood Transfus. 2019; 35(2):284-91. doi: 10.1007/s12288-018-1034-x.

Musallam KM, Vitrano A, Meloni A, et al. Primary HBB gene mutation severity and long-term outcomes in a global cohort of β-thalassaemia. Br J Haematol. 2022; 196 (2) : 414-423. doi: 10.1111/bjh.17897.

Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994; 331(9):574-8. doi: 10.1056/ NEJM199409013310903.

De Sanctis V, Elsedfy H, Soliman AT, et al. (Endocrine profile of β-thalassemia major patients followed from childhood to advanced adulthood in a tertiary care center. Indian J Endocrinol Metab. 2016; 20(4):451-9. doi: 10.4103/2230-8210.183456.

Bordbar M, Bozorgi H, Saki F, et al. Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients: a historical cohort study in Southern Iran. J Endocrinol Invest. 2019; 42 (12):1467–76. doi: 10.1007/s40618-019-01072-z.

Vogiatzi MG, Macklin EA, Trachtenberg FL, et al. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassemia syndromes in North America. Br J Haematol. 2009; 146(5): 546–56. doi: 10.1111/j.1365-2141.2009.07793.x.

Pinto VM, Poggi M, Russo R, Giusti A, Forni GL. Management of the aging beta-thalassemia transfusion-dependent population - The Italian experience. Blood Rev. 2019; 38:100594. doi: 10.1016/j.blre.2019.100594.

Wu H-P, Lin C-L, Chang Y-C, et al. Survival and complication rates in patients with thalassemia major in Taiwan. Pediatr Blood Cancer. 2017; 64(1): 135–8. doi: 10.1002/ pbc.26181.

Yaghobi M, Miri-Moghaddam E, Majid N, Bazi A, Navidian A, Kalkali A. Complications of Transfusion-Dependent β-Thalassemia Patients in Sistan and Baluchistan, South-East of Iran. J Hematol Oncol Stem Cell Res. 2017;11(4):268-72. PMID: 29340121.

Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with Thalassaemia Major. Pediatr Endocrinol Rev. 2007; 5(2):642-8. PMID: 18084158.

Jobanputra M, Paramore C, Laird SG, McGahan M, Telfer P. Co-morbidities and mortality associated with transfusion-dependent beta-thalassaemia in patients in England: a 10-year retrospective cohort analysis. Br J Haematol. 2020; 191: 897–905. doi: 10.1111/bjh.17091.

Mula-Abed W-A, Al Hashmi H, Al Muslahi M, Al Muslahi H, Al Lamki M. Prevalence of Endocrinopathies in Patients with Beta-Thalassaemia Major - A Cross-Sectional Study in Oman. Oman Med J. 2008; 23(4):257-62 PMID: 22334838.

He L-N, Chen W, Yang Y, et al. Elevated Prevalence of Abnormal Glucose Metabolism and Other Endocrine Disorders in Patients with β -Thalassemia Major: A Meta-Analysis. Biomed Res Int. 2019; 2019:6573497. doi: 10.1155/2019/6573497.

Pinto VM, Bacigalupo L, Gianesin B, et al. Lack of correlation between heart, liver and pancreas MRI-R2*: Results from long-term follow-up in a cohort of adult β-thalassemia major patients. Am J Hematol. 2018; 93(3):E79-E82. doi: 10.1002/ajh.25009.

Calleja EM, Shen JY, Lesser M, Grady RW, New MI, Giardina PJ. Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience. Ann N Y Acad Sci. 1998; 850:469-70. doi: 10.1111/j.1749-6632.1998.tb10524.x.

Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002; 100(1):17-21. doi:10.1182/blood.V100.1.17.

Elalfy MS, Esmat G, Matter RM, Abdel Aziz HEA, Massoud WA. Liver fibrosis in young Egyptian beta-thalassemia major patients: Relation to hepatitis C virus and compliance with chelation. Ann Hepatol. 2013; 12(1):54-61. doi:10.1016/s1665-2681(19)31385-7.

De Sanctis V, Soliman AT, Daar S, et al. A concise review on the frequency, major risk factors and surveillance of hepatocellular carcinoma (HCC) in β-thalassemias: Past, present and future perspectives and the ICET - A experience. Mediterr J Hematol Infect Dis. 2020; 12(1):e2020006. doi: 10.4084/MJHID.2020.006.

Downloads

Published

03-08-2023

Issue

Section

ORIGINAL CLINICAL RESEARCH

How to Cite

1.
Daar S, Al-Naamani K, de Sanctis V, Al Rahbi S, Al Zadjali S, Khan H, et al. Mortality and complications in Omani patients with beta-thalassemia major: a long-term follow-up study. Acta Biomed [Internet]. 2023 Aug. 3 [cited 2024 Jul. 12];94(4):e2023191. Available from: https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/14856